lenalidomide has been researched along with sgi 1776 in 2 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (sgi 1776) | Trials (sgi 1776) | Recent Studies (post-2010) (sgi 1776) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 59 | 0 | 56 |
| Protein | Taxonomy | lenalidomide (IC50) | sgi 1776 (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase Yes | Homo sapiens (human) | 1.455 | |
| Serine/threonine-protein kinase pim-1 | Homo sapiens (human) | 0.0158 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.007 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.362 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 0.0382 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.069 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.8727 | |
| Serine/threonine-protein kinase pim-3 | Homo sapiens (human) | 0.0659 | |
| Serine/threonine-protein kinase haspin | Homo sapiens (human) | 0.034 | |
| Serine/threonine-protein kinase pim-2 | Homo sapiens (human) | 0.4053 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Chao, N; Ebens, A; Foreman, O; Gasparetto, C; Hu, J; Kang, Y; Kozlowski, C; Lazarchick, J; Roof, L; Sha, Y; Venkta, JK; Zheng, J | 1 |
2 other study(ies) available for lenalidomide and sgi 1776
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.
Topics: Adaptor Proteins, Signal Transducing; Animals; Down-Regulation; Humans; Ikaros Transcription Factor; Imidazoles; Lenalidomide; Mice; Mice, Inbred C57BL; Multiple Myeloma; Peptide Hydrolases; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-pim-1; Pyridazines; Signal Transduction; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2019 |